Table 1 .
Clinical trials in GBM as found in ClinicalTrials.gov (2005–2016) as of April 3, 2017
| NA | Phase I | Phase I/II | Phase II | Phase II/III | Phase III | Phase IV | Total | |
|---|---|---|---|---|---|---|---|---|
| Trials | ||||||||
| Number of trials | 13 (3%) | 136 (33%) | 83 (20%) | 166 (40%) | 2 (0.5%) | 16 (4%) | 1 (0.2%) | 417 (100%) |
| Trial status* | ||||||||
| Completed | 2 | 52 | 17 | 72 | – | 8 | – | 151 (36%) |
| Active, not recruiting | 4 | 23 | 23 | 31 | 1 | 4 | – | 86 (21%) |
| Recruiting | 7 | 43 | 25 | 32 | – | 3 | – | 110 (26%) |
| Not yet recruiting | – | 1 | – | 2 | – | – | – | 3 (0.7%) |
| Enrolling by invitation | – | – | 1 | – | – | – | – | 1 (0.2%) |
| Suspended | – | 2 | 1 | – | 1 | – | – | 4 (1%) |
| Terminated | – | 12 | 10 | 21 | – | 1 | 1 | 45 (11%) |
| Withdrawn | – | 1 | 1 | 2 | – | – | – | 4 (1%) |
| Unknown status | – | 2 | 5 | 6 | – | – | – | 13 (3%) |
| GBM classification | ||||||||
| Newly diagnosed | 3 | 39 | 29 | 54 | 1 | 10 | – | 136 (33%) |
| Recurrent | 10 | 91 | 53 | 110 | 1 | 5 | 1 | 271 (65%) |
| Both | – | 5 | 1 | 2 | – | 1 | – | 9 (2%) |
| Not specified | – | 1 | – | – | – | – | – | 1 (0.2%) |
| Results provided** | ||||||||
| Results provided | – | 1 | 22 | 67 | – | 6 | – | 96 (23%) |
| Publication provided**† | ||||||||
| Publication provided | 2 | 22 | 15 | 39 | 2 | 11 | 1 | 92 (22%) |
| Results publication provided | 1 | 9 | 8 | 26 | – | 8 | – | 52 (12%) |
*See Supplementary Table S1 for definitions provided by ClinicalTrials.gov.
**In ClinicalTrials.gov.
†Provided publications need not be reporting on trial results. We distinguish between all publications provided (92 trials), and those that report trial results for primary outcomes (52 trials).